Short interfering RNA guide strand modifiers from computational screening.

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Short interfering RNAs (siRNAs) are potent therapeutic agents targeting diverse diseases.
• Native RNA structures present limitations for siRNA drug development, necessitating chemical modifications.
• The human Argonaute 2 (hAgo2) protein is central to RNA interference (RNAi) pathway efficacy.

Purpose of the Study:

• To discover functional chemical modifications for the 5 eal-end of siRNA guide strands.
• To utilize computational screening and structural data of hAgo2 for guiding modification discovery.
• To expand the range of nucleotide analogues for enhanced siRNA therapeutics.

Main Methods:

• Structure-guided computational screening of potential siRNA modifications.
• Utilizing the high-resolution structure of human Ago2 (hAgo2).
• Synthesizing and testing 1,2,3-triazol-4-yl bases and purine derivatives in RNA.

Main Results:

• The 5 eal-end nucleotide of siRNA guide strands requires appropriate shape complementarity in the hAgo2 binding site, not necessarily Watson-Crick H-bonding.
• 1,2,3-Triazol-4-yl bases, synthesized via CuAAC reaction, are effective modifications at the siRNA 5 eal-end.
• Purine derivatives with modified Hoogsteen faces or N2 substituents were found to be unsuitable for 5 eal-end modification.
• A 1,2,3-triazol-4-yl base lacking Watson-Crick H-bonding capability showed efficacy at position 12 of the guide strand.

Conclusions:

• Functional siRNA modifications can be discovered through structure-guided computational approaches.
• Novel nucleotide analogues, such as 1,2,3-triazol-4-yl bases, offer new possibilities for siRNA drug design.
• Understanding hAgo2-siRNA interactions is key to developing more effective siRNA therapeutics.